PAXLOVID™ (nirmatrelvir with ritonavir) and Lagevrio (molnupiravir) is an oral antiviral used to tread COVID-19 positive patients. Preliminary evidence suggests PAXLOVID™ and Lagevrio is effective against Omicron. It reduces the risk of hospitalisation for those who have a higher risk of hospitalisation or becoming seriously unwell.